Sage Therapeutics Inc (NASDAQ:SAGE)’s traded shares stood at 0.7 million during the last session, with the company’s beta value hitting 0.95. At the close of trading, the stock’s price was $11.90, to imply a decrease of -3.57% or -$0.44 in intraday trading. The SAGE share’s 52-week high remains $59.99, putting it -404.12% down since that peak but still an impressive 8.24% since price per share fell to its 52-week low of $10.92. The company has a valuation of $716.14M, with an average of 1.07 million shares over the past 3 months.
Sage Therapeutics Inc (NASDAQ:SAGE) trade information
After registering a -3.57% downside in the last session, Sage Therapeutics Inc (SAGE) has traded red over the past five days. The stock hit a weekly high of 14.31, dropping -3.57% in its intraday price action. The 5-day price performance for the stock is -14.63%, and -28.18% over 30 days. With these gigs, the year-to-date price performance is -45.09%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sage Therapeutics Inc (SAGE) estimates and forecasts
Looking at statistics comparing Sage Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Sage Therapeutics Inc (SAGE) shares are -35.68% down over the last 6 months, with its year-to-date growth rate higher than industry average at 27.85% against 12.00%.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -2.28% for the past 5-year period. While 2024 is set for a 28.60% return in earnings, projections for the next 5 years are at 16.80% annually.
SAGE Dividends
Sage Therapeutics Inc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Sage Therapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
